QYUNS-B (02509) Gains Approval for Marketing Authorization and Supplemental Application of QX001S (Ustekinumab Injection) for Crohn's Disease

Stock News

May 21

QYUNS-B (02509) announced that Sino-American East China recently received the "Drug Registration Certificate" and "Drug Supplemental Application Approval Notice" issued by the National Medical Products Administration (NMPA). The marketing authorization application and supplemental application for Ustekinumab Injection (Intravenous Infusion) (brand name: Saijiening®) and Ustekinumab Injection (brand name: Sailexin®, R&D code: QX001S/HDM3001-2) for the treatment of Crohn's disease have been approved.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1193332535"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1193332535\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1193332535?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-21 20:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1193332535","market":"sg","top_or_hot":-1,"title":"QYUNS-B (02509) Gains Approval for Marketing Authorization and Supplemental Application of QX001S (Ustekinumab Injection) for Crohn's Disease","media":"Stock News","content":"<p>QYUNS-B (02509) announced that Sino-American East China recently received the \"Drug Registration Certificate\" and \"Drug Supplemental Application Approval Notice\" issued by the National Medical Products Administration (NMPA). The marketing authorization application and supplemental application for Ustekinumab Injection (Intravenous Infusion) (brand name: Saijiening®) and Ustekinumab Injection (brand name: Sailexin®, R&D code: QX001S/HDM3001-2) for the treatment of Crohn's disease have been approved.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>QYUNS-B (02509) Gains Approval for Marketing Authorization and Supplemental Application of QX001S (Ustekinumab Injection) for Crohn's Disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQYUNS-B (02509) Gains Approval for Marketing Authorization and Supplemental Application of QX001S (Ustekinumab Injection) for Crohn's Disease\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-21 20:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>QYUNS-B (02509) announced that Sino-American East China recently received the \"Drug Registration Certificate\" and \"Drug Supplemental Application Approval Notice\" issued by the National Medical Products Administration (NMPA). The marketing authorization application and supplemental application for Ustekinumab Injection (Intravenous Infusion) (brand name: Saijiening®) and Ustekinumab Injection (brand name: Sailexin®, R&D code: QX001S/HDM3001-2) for the treatment of Crohn's disease have been approved.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1193332535","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1193332535","pubTimestamp":1779367695,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"QYUNS-B (02509) announced that Sino-American East China recently received the \"Drug Registration Certificate\" and \"Drug Supplemental Application Approval Notice\" issued by the National Medical...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02509":"荃信生物-B","IPOS":"Renaissance International IPO ETF"},"translate_title":"QYUNS-B(02509)获得QX001S（乌司奴单抗注射液）治疗克罗恩病的上市许可和补充申请批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IPOS":1,"02509":1},"content_text":"QYUNS-B (02509) announced that Sino-American East China recently received the \"Drug Registration Certificate\" and \"Drug Supplemental Application Approval Notice\" issued by the National Medical Products Administration (NMPA). The marketing authorization application and supplemental application for Ustekinumab Injection (Intravenous Infusion) (brand name: Saijiening®) and Ustekinumab Injection (brand name: Sailexin®, R&D code: QX001S/HDM3001-2) for the treatment of Crohn's disease have been approved.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}